The FDA has approved Leqembi, an injectable form of Eisai and Biogen’s Alzheimer’s drug, permitting weekly maintenance dosing that can be administered at patients’ homes. This regulatory milestone represents an advancement in delivering complex neurological therapies more conveniently, potentially improving patient adherence and quality of life. The decision comes alongside several other FDA approvals for rare disease drugs and adjusted indications for COVID-19 vaccines.